查看购物车
  • Traditional Chinese
  • English
  • Japanese
2031年北美青光眼治疗市场预测 - 区域分析 - 按药物类别、适应症和配销通路
市场调查报告书
商品编码
1764891

2031年北美青光眼治疗市场预测 - 区域分析 - 按药物类别、适应症和配销通路

North America Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class, Indication, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 132 Pages | 订单完成后即时交付

价格

2023 年北美青光眼治疗市场价值为 26.3452 亿美元，预计到 2031 年将达到 34.2164 亿美元；预计 2023 年至 2031 年的复合年增长率为 3.3%。

青光眼发生率不断上升推动北美青光眼治疗市场

青光眼是一种因视神经受损引起的眼部疾病，最终可能导致完全失明。青光眼患者可能会逐渐经历神经组织损失，如果不及时治疗，会导致视力下降或失明。全球青光眼病例正在显着增加。根据青光眼研究基金会的数据，到 2040 年，全球预计将有 2,200 万人因青光眼而失明。此外，根据世界卫生组织的数据，青光眼是全球主要的失明原因，影响超过 6,000 万人，导致约 450 万人失明。根据 2021 年 1 月发表在《视觉与眼科学研究协会》（ARVO）杂誌上的一篇文章的估计，到 2030 年底、2040 年底和 2050 年底，墨西哥患有青光眼的人数将分别达到 250 万人、300 万人和 340 万人。随着全球青光眼病例数量的不断增加，对青光眼治疗的需求也日益增长。用于治疗青光眼的医疗和外科手术主要着重于降低眼压 (IOP)。前列腺素类似物是广泛推荐的药物之一，可透过促进眼球引流来有效降低眼压。由于其疗效显着且不良反应有限，这些产品已成为青光眼治疗的主流方案。

北美洲青光眼治疗市场概况

根据美国人口参考局 2019 年的数据，到 2060 年，美国 65 岁及以上人口的数量预计将从 2018 年的 5,200 万（占总人口的 16%）翻一番，增至近 9,500 万人（占总人口的 23%）。美国眼科学会 2019 年进行的一项研究表明，到 2050 年，美国 70-75 岁人群估计将有近 732 万人患有原发性开角型青光眼 (POAG)。因此，美国青光眼治疗市场的成长主要受眼部疾病盛行率上升的推动，尤其是在老年人口中。美国占北美青光眼治疗市场的最大份额。

市场参与者采用的各种有机和无机成长策略也为美国青光眼治疗市场的发展做出了显着贡献。以下列举了一些此类成长策略。

2023年10月，Stuart Therapeutics与Glaukos签署了Stuart Therapeutics ST-113候选药物的授权协议，该药物旨在保护青光眼患者的神经。 2022年8月，爱尔康收购了Aerie Pharmaceuticals, Inc.。这项交易证实了爱尔康对眼科药物领域的承诺，并有望透过增加更广泛的药物研发能力来增强其现有的商业专长，从而最大限度地提升其多元化产品组合的价值。北美青光眼治疗市场收入及预测（2031年）（百万美元）

北美青光眼治疗市场细分

北美青光眼治疗市场按药物类别、适应症、配销通路和国家分类。

依药物类别，北美青光眼治疗市场细分为β受体阻断剂、α肾上腺素激动剂、前列腺素类似物、碳酸酐酶抑制剂、复方药物及其他。前列腺素类似物在2023年占据了最大的市场。

根据适应症，北美青光眼治疗市场分为开角型青光眼、闭角型青光眼和其他类型。 2023年，开角型青光眼占了最大的市场。

按配销通路划分，北美青光眼治疗市场分为医院药房、零售药房和线上药房。 2023年，医院药局占了最大的市场份额。

按国家/地区划分，北美青光眼治疗市场分为美国、加拿大和墨西哥。 2023年，美国占据了北美青光眼治疗市场的主导地位。

Alcon AG、AbbVie Inc、Bausch & Lomb Inc、Fera Pharmaceuticals, LLC、Viatris Inc、Novartis AG、Sun Pharmaceutical Industries Ltd、Teva Pharmaceuticals Industries Ltd、Thea Pharma Inc 和 Santen Pharmaceutical Co., Ltd. 是北美青光眼治疗市场领先的公司。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力

第三章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 显影基数：
    • 数据三角测量：
    • 国家级资料：

第四章：北美青光眼治疗市场格局

  • 概述
  • PEST分析

第五章：北美青光眼治疗市场-关键市场动态

  • 市场驱动因素
    • 青光眼发生率不断上升
    • 产品发布、合作和收购的数量不断增加
  • 市场限制
    • 药物治疗方案依从性问题
  • 市场机会
    • 穿戴式科技的发展
  • 未来趋势
    • 新型药物输送方法的开发
  • 驱动因素和限制因素的影响：

第六章：青光眼治疗市场－北美分析

  • 2021-2031年青光眼治疗市场收入
  • 青光眼治疗市场预测分析

第七章：北美青光眼治疗市场分析－依药物类别

  • β受体阻断剂
  • α肾上腺素激动剂
  • 前列腺素类似物
  • 碳酸酐酶抑制剂
  • 联合用药
  • 其他的

第 8 章：北美青光眼治疗市场分析 - 按适应症

  • 开角型青光眼
  • 闭角型青光眼
  • 其他的

第九章：北美青光眼治疗市场分析－按配销通路

  • 医院药房
  • 零售药局
  • 网路药局

第 10 章：北美青光眼治疗市场 - 国家分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

第 11 章：青光眼治疗市场-产业格局

  • 青光眼治疗市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第十二章：公司简介

  • Alcon AG
  • AbbVie Inc
  • Bausch & Lomb Inc
  • Fera Pharmaceuticals, LLC
  • Viatris Inc
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Thea Pharma Inc
  • Santen Pharmaceutical Co., Ltd.

第 13 章：附录

Product Code: BMIRE00031610

The North America glaucoma therapeutics market was valued at US$ 2,634.52 million in 2023 and is expected to reach US$ 3,421.64 million by 2031; it is estimated to register a CAGR of 3.3% from 2023 to 2031.

Mounting Incidence of Glaucoma Disease Fuels North America Glaucoma Therapeutics Market

Glaucoma is an eye disorder caused due to the damaged optic nerve, which can eventually lead to total blindness. Glaucoma patients may experience a gradual loss of nerve tissue, resulting in vision impairment or blindness if left untreated. Glaucoma cases are increasing significantly across the world. As per the Glaucoma Research Foundation, an estimated 22 million people worldwide would attain blindness due to glaucoma by 2040. Further, Glaucoma is a leading cause of blindness worldwide, affecting over 60 million people and leading to approximately 4.5 million cases of blindness, according to the World Health Organization. According to estimates provided in an article published in the Association for Research in Vision and Ophthalmology (ARVO) Journal in January 2021, the number of people suffering from glaucoma in Mexico would reach 2.5 million, 3 million, and 3.4 million by the end of 2030, 2040, and 2050, respectively. The demand for glaucoma treatments is increasing with the rising number of glaucoma cases in the global population. Medical and surgical procedures meant to manage this disease focus on lowering intraocular pressure (IOP). Prostaglandin analogs are among the drugs widely recommended for effectively reducing IOP by promoting better drainage from the eye. These products have been mainstream glaucoma treatment due to their efficacy and limited adverse effects.

North America Glaucoma Therapeutics Market Overview

As per the Population Reference Bureau 2019, the number of individuals aged 65 and above in the US is estimated to double from 52 million (16% of the total population) in 2018 to nearly 95 million (23% of the total population) by 2060. A study conducted by the American Academy of Ophthalmology in 2019 states that nearly 7.32 million people aged 70-75 is estimated to be affected by primary open-angle glaucoma (POAG) in the US by 2050. Thus, the glaucoma therapeutics market growth in the US is primarily driven by the increasing prevalence of eye diseases, especially in the geriatric population. The US accounts for the largest share of the glaucoma therapeutics market in North America.

Various organic and inorganic growth strategies adopted by market players also contribute notably to the glaucoma therapeutics market progress in the US. A few of such growth strategies are mentioned below.

In October 2023, Stuart Therapeutics and Glaukos signed a license agreement for Stuart Therapeutics' ST-113 drug candidate designed for neuroprotection in glaucoma. In August 2022, Alcon acquired Aerie Pharmaceuticals, Inc. This transaction confirms Alcon's commitment to the ophthalmic pharmaceutical space, and it is expected to enhance its existing commercial expertise by adding broader pharmaceutical R&D capabilities, thereby maximizing the value of its diversified portfolio. North America Glaucoma Therapeutics Market Revenue and Forecast to 2031 (US$ Million)

North America Glaucoma Therapeutics Market Segmentation

The North America glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.

Based on drug class, the North America glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.

In terms of indication, the North America glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.

By distribution channel, the North America glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.

By country, the North America glaucoma therapeutics market is segmented into the US, Canada, and Mexico. The US dominated the North America glaucoma therapeutics market share in 2023.

Alcon AG, AbbVie Inc, Bausch & Lomb Inc, Fera Pharmaceuticals, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the North America glaucoma therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. North America Glaucoma Therapeutics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. North America Glaucoma Therapeutics Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Mounting Incidence of Glaucoma Disease
    • 5.1.2 Increasing Number of Product Launches, Collaborations, and Acquisitions
  • 5.2 Market Restraints
    • 5.2.1 Medication Regimen Compliance Issues
  • 5.3 Market Opportunities
    • 5.3.1 Development of Wearable Technologies
  • 5.4 Future Trends
    • 5.4.1 Development of Novel Drug Delivery Methods
  • 5.5 Impact of Drivers and Restraints:

6. Glaucoma Therapeutics Market - North America Analysis

  • 6.1 Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
  • 6.2 Glaucoma Therapeutics Market Forecast Analysis

7. North America Glaucoma Therapeutics Market Analysis - by Drug Class

  • 7.1 Beta Blockers
    • 7.1.1 Overview
    • 7.1.2 Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Alpha Adrenergic Agonists
    • 7.2.1 Overview
    • 7.2.2 Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Prostaglandins Analogues
    • 7.3.1 Overview
    • 7.3.2 Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Carbonic Anhydrase Inhibitors
    • 7.4.1 Overview
    • 7.4.2 Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Combination Drugs
    • 7.5.1 Overview
    • 7.5.2 Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

8. North America Glaucoma Therapeutics Market Analysis - by Indication

  • 8.1 Open Angle Glaucoma
    • 8.1.1 Overview
    • 8.1.2 Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Angle Closure Glaucoma
    • 8.2.1 Overview
    • 8.2.2 Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Others
    • 8.3.1 Overview
    • 8.3.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Glaucoma Therapeutics Market Analysis - by Distribution Channel

  • 9.1 Hospital Pharmacy
    • 9.1.1 Overview
    • 9.1.2 Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Retail Pharmacy
    • 9.2.1 Overview
    • 9.2.2 Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Online Pharmacy
    • 9.3.1 Overview
    • 9.3.2 Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

10. North America Glaucoma Therapeutics Market - Country Analysis

  • 10.1 North America
    • 10.1.1 North America: Glaucoma Therapeutics Market Breakdown, by Key Country, 2023 and 2031 (%)
      • 10.1.1.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.2.1 United States: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.2.2 United States: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.1.1.2.3 United States: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.3 Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.3.1 Canada: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.3.2 Canada: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.1.1.3.3 Canada: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.4 Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.4.1 Mexico: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.4.2 Mexico: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.1.1.4.3 Mexico: Glaucoma Therapeutics Market Breakdown, by Distribution Channel

11. Glaucoma Therapeutics Market - Industry Landscape

  • 11.1 Growth Strategies in Glaucoma Therapeutics Market
  • 11.2 Organic Growth Strategies
    • 11.2.1 Overview
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview

12. Company Profiles

  • 12.1 Alcon AG
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 AbbVie Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Bausch & Lomb Inc
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Fera Pharmaceuticals, LLC
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Viatris Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Novartis AG
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Sun Pharmaceutical Industries Ltd
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Teva Pharmaceutical Industries Ltd
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Thea Pharma Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Santen Pharmaceutical Co., Ltd.
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. North America Glaucoma Therapeutics Market Segmentation
  • Table 2. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Table 3. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 4. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 5. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 6. North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Country
  • Table 7. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 8. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 9. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 10. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 11. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 12. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 13. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 14. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 15. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 16. Recent Organic Growth Strategies in Glaucoma Therapeutics Market
  • Table 17. Recent Inorganic Growth Strategies in the Glaucoma Therapeutics Market
  • Table 18. Glossary of Terms

List Of Figures

  • Figure 1. North America Glaucoma Therapeutics Market Segmentation, by Country
  • Figure 2. PEST Analysis
  • Figure 3. Glaucoma Therapeutics Market - Key Market Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
  • Figure 6. Glaucoma Therapeutics Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 7. Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Glaucoma Therapeutics Market Share (%) - by Indication (2023 and 2031)
  • Figure 14. Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Glaucoma Therapeutics Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 18. Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. North America Glaucoma Therapeutics Market, by Key Country - Revenue (2023) (US$ Million)
  • Figure 22. North America: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 23. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Growth Strategies in Glaucoma Therapeutics Market